Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
October 05 2021 - 7:00AM
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”)
(Nasdaq: FNCH), a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel
class of orally administered biological drugs, today announced that
Samuel Allen (Al) Hamood has joined Finch’s Board of Directors. Mr.
Hamood is an accomplished executive with over 30 years of
experience in finance, business development, corporate strategy,
and M&A across several global industry sectors.
“Through the course of his career, Al has been instrumental in
developing and driving growth strategies and translating those
strategies into operational successes across multiple global
industry verticals,” said Mark Smith, PhD, Chief Executive Officer
of Finch Therapeutics. “We are excited to welcome him to our board
and look forward to leveraging his deep finance expertise as we
advance our platform and pipeline of investigational microbiome
therapeutics.”
“I am greatly impressed by the progress Finch is making in the
microbiome therapeutics space, highlighted by their late-stage
CP101 program addressing a serious unmet need and their
differentiated platform and pipeline with multiple near-term
clinical milestones,” said Mr. Hamood. “I look forward to working
closely with the management team and my fellow board members to
continue executing on Finch’s strategy, with the goal of delivering
value to both patients and shareholders.”
Mr. Hamood is currently the President and Chief Administrative
and Financial Officer of Culligan International, a
multi-billion-dollar global consumer water services corporation
operating in over 90 countries. Prior to Culligan, Mr. Hamood
served as the acting Chief Executive Officer and President of ATI
Physical Therapy, where he managed nearly 1,000 clinics and led
over 8,000 employees. Before joining ATI, he served as Executive
Vice President and Chief Financial Officer for Change Healthcare, a
multi-billion-dollar healthcare technology company. Prior to
joining Change Healthcare, Mr. Hamood was the Executive Vice
President and Chief Financial Officer of TransUnion, a
multinational global information services company. Earlier in his
career he held a variety of finance and strategy roles at Hewlett
Packard (formerly known as “EDS”), the Walt Disney Company, and
Deloitte & Touche.
Mr. Hamood earned his Bachelor of Business Administration from
the University of Iowa and his Juris Doctorate from Southwestern
University School of Law. He is a Certified Public Accountant, and
currently serves on the Board of Directors for Definitive
Healthcare and AccentCare and is a member of the CNBC CFO
Council.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics
company leveraging its Human-First Discovery® platform to develop a
novel class of orally administered biological drugs. With the
capabilities to develop both complete and targeted microbiome
therapeutics, Finch is advancing a rich pipeline of candidates
designed to address a wide range of unmet medical needs. Finch’s
lead candidate, CP101, is in late-stage clinical development for
the prevention of recurrent C. difficile infection (CDI), and has
received Breakthrough Therapy and Fast Track designations from the
U.S. Food and Drug Administration. In June 2020, Finch announced
that CP101 met its primary efficacy endpoint in PRISM3, the first
of two pivotal trials to support the development of CP101 for the
prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed
to serve as the second pivotal trial of CP101 for recurrent CDI.
Finch is also developing CP101 for the treatment of chronic
hepatitis B virus, and FIN-211 for the treatment of the
gastrointestinal and behavioral symptoms of autism spectrum
disorder. Finch has a partnership with Takeda focused on the
development of targeted microbiome therapeutics for inflammatory
bowel disease.
Human-First Discovery® is a registered trademark of Finch
Therapeutics Group, Inc.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as “anticipates,” “believes,”
“expects,” “intends,” “plans,” “potential,” "projects,” “would” and
“future” or similar expressions are intended to identify
forward-looking statements. These forward-looking statements
include, but are not limited to, statements regarding: Finch’s
ability to execute on its business strategy and plans, including
advancement of its platform and pipeline of microbiome
therapeutics. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, among others: Finch’s limited
operating history and historical losses; Finch’s ability to raise
additional funding to complete the development and any
commercialization of its product candidates; Finch’s dependence on
the success of its lead product candidate, CP101; the possibility
that Finch may be delayed in initiating, enrolling or completing
any clinical trials; results of clinical trials may not be
indicative of final or future results from later stage or larger
clinical trials (or in broader patient populations once the product
is approved for use by regulatory agencies) or may not be favorable
or may not support further development; Finch’s product candidates
may not generate the benefits to patients that are anticipated;
anticipated regulatory approvals may be delayed or refused;
competition from third parties that are developing products for
similar uses; Finch’s ability to maintain patent and other
intellectual property protection and the possibility that Finch’s
intellectual property rights may be infringed, invalid or
unenforceable or will be threatened by third parties; Finch’s
ability to qualify and scale its manufacturing capabilities in
anticipation of commencement of multiple global clinical trials;
Finch’s lack of experience in selling, marketing and distributing
its product candidates; Finch’s dependence on third parties in
connection with manufacturing, clinical trials and preclinical
studies; and risks relating to the impact and duration of the
COVID-19 pandemic on Finch’s business. These and other risks are
described more fully in Finch’s filings with the Securities and
Exchange Commission (“SEC”), including the section titled “Risk
Factors” in Finch’s Quarterly Report on Form 10-Q filed with the
SEC on August 10, 2021, as well as discussions of potential risks,
uncertainties, and other important factors in Finch’s other filings
with the SEC. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Except to the extent required by law, Finch undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor Contact:
Laurence WattsGilmartin Group(619)
916-7620laurence@gilmartinir.com
or
Stephen JasperGilmartin Group(858)
525-2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public
Relations212-253-8881jurban@berrypr.com
Finch Therapeutics (NASDAQ:FNCH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Finch Therapeutics (NASDAQ:FNCH)
Historical Stock Chart
From Jul 2023 to Jul 2024